FDA digital-health technology funding window closed August 20, 2026

Why it matters

The historical opportunity identifies FDA measurement priorities; it does not establish an award, a validated measure, endpoint acceptance, guidance, or clinical benefit.

Decision implication

Monitor for awardees, selected modalities, endpoint methods, validation work, and resulting guidance or precedents.

Who or what is affected

FDA
drug developers
DHT developers
researchers
trial sponsors

Evidence and sources

Decision priority: Historical

Source authority: Primary/authoritative · official FDA source

Evidence design: Program record

Applicability: Direct

Confidence for the stated claim: High

Freshness: Historical

https://www.fda.gov/science-research/science-and-research-special-topics/digital-health-technologies-dhts-drug-development

This record separates source facts from P4L interpretation. Program participation, a proposal, funding, or a public listing does not by itself establish clinical effectiveness, endorsement, coverage, or scaled adoption.

For this decision

Researchers · Innovators · Funders/investors · Policymakers · Clinicians

What P4L is watching next

Awardees
Selected modalities
Endpoint methods
Validation work
Resulting guidance or precedents

Related proof records

CLM-0008 — FDA announced a funding opportunity that was open from July 20 through August 20, 2026, for projects exploring digital health technologies in drug development, including actigraphy, photography, and contactless sensors. The application window is closed. P4L is now watching for awardees, selected modalities, endpoint methods, validation work, and resulting guidance or precedents.

Record provenance

Last verified: 2026-09-03
Source updated: 2026-08-20
Status: Historical · application window closed
Freshness: Historical
Version: 1.0
Stable ID: SIG-2026-015